Difference between revisions of "Sevoflurane"
(New page: {{unfinished}} '''Sevoflurane''' is very similar to isoflurane but is less potent. However, it's odour is less pungent making it more suitable for mask induction, but can a...) |
|||
| (4 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
| − | + | ==Introduction== | |
| − | |||
'''Sevoflurane''' is very similar to [[Isoflurane|isoflurane]] but is less potent. However, it's odour is less pungent making it more suitable for mask induction, but can also be used as a maintentance agent. It is becoming more popular in veterinary anaesthesia. | '''Sevoflurane''' is very similar to [[Isoflurane|isoflurane]] but is less potent. However, it's odour is less pungent making it more suitable for mask induction, but can also be used as a maintentance agent. It is becoming more popular in veterinary anaesthesia. | ||
==Pharmacokinetics== | ==Pharmacokinetics== | ||
| − | Sevoflurane is also a halogenated ether. It is also stable and nonflammable. Alkaline carbon dioxide absorbents react with sevoflurane to produced a potentially toxic compound. This can be influenced by environmental temperature, sevoflurane concentrations, use of baralyme rather then sodalime, low flow rates and already exposed absorbents. The '''blood:gas partition coefficient''' is very low, meaning that has a rapid onset of action. It has a high tissue solubility however, which means that recovery is more prolonged compared to [[Isoflurane|isoflurane]] or [[Halothane|halothane]]. The '''MAC''' of sevoflurane is approximately ''2. | + | Sevoflurane is also a halogenated ether. It is also stable and nonflammable. Alkaline carbon dioxide absorbents react with sevoflurane to produced a potentially toxic compound. This can be influenced by environmental temperature, sevoflurane concentrations, use of baralyme rather then sodalime, low flow rates and already exposed absorbents. The '''blood:gas partition coefficient''' is very low, meaning that has a rapid onset of action. It has a high tissue solubility however, which means that recovery is more prolonged compared to [[Isoflurane|isoflurane]] or [[Halothane|halothane]]. The '''MAC''' of sevoflurane is approximately ''2.4%'' in dogs and ''2.6%'' in cats and is therefore less potent than other agents. Sevoflurane undergoes a small amount of hepatic metabolism. |
==Adverse Effects== | ==Adverse Effects== | ||
| Line 19: | Line 18: | ||
==Contraindications== | ==Contraindications== | ||
*It is advisable to avoid the use of sevoflurane in patients with renal disease as there is a potential for further renal damage. | *It is advisable to avoid the use of sevoflurane in patients with renal disease as there is a potential for further renal damage. | ||
| + | |||
| + | |||
| + | {{unfinished}} | ||
| + | [[Category:To Do - Drugs]][[Category:To Do - Anaesthesia]] | ||
| + | [[Category:Inhalation Anaesthetic Agents]] | ||
Latest revision as of 09:17, 18 September 2012
Introduction
Sevoflurane is very similar to isoflurane but is less potent. However, it's odour is less pungent making it more suitable for mask induction, but can also be used as a maintentance agent. It is becoming more popular in veterinary anaesthesia.
Pharmacokinetics
Sevoflurane is also a halogenated ether. It is also stable and nonflammable. Alkaline carbon dioxide absorbents react with sevoflurane to produced a potentially toxic compound. This can be influenced by environmental temperature, sevoflurane concentrations, use of baralyme rather then sodalime, low flow rates and already exposed absorbents. The blood:gas partition coefficient is very low, meaning that has a rapid onset of action. It has a high tissue solubility however, which means that recovery is more prolonged compared to isoflurane or halothane. The MAC of sevoflurane is approximately 2.4% in dogs and 2.6% in cats and is therefore less potent than other agents. Sevoflurane undergoes a small amount of hepatic metabolism.
Adverse Effects
Central Nervous System
- Increases intracranial pressure due to cerebral vasodilation.
Cardiovascular System
- Mild myocardial contractility depression.
- Decreased arterial blood pressure and systemic vascular resistance.
Other Systems
- There is an increase in hepatic artery flow, but reduced in the hepatic portal vein, like isoflurane.
Contraindications
- It is advisable to avoid the use of sevoflurane in patients with renal disease as there is a potential for further renal damage.
 |
This article is still under construction. |